The dengue virus,a member of the Flavivirus genus within the Flaviviridae family,is responsible for dengue fever,an acute mosquito-borne infectious disease that can progress to severe forms such as dengue hemorrhagic fever and dengue shock syndrome,taking a heavy toll on human health.Despite its impact on global public health,there are currently no specific drugs available that are both safe and effective for the treatment of dengue fever so that the research and development of related drugs are facing huge challenges.This paper not only pointed to the critical importance and urgency of developing antiviral medications,but also reviewed recent advancements in the development of dengue virus inhibitors of two categories:candidate drugs that directly target viral structural and non-structural proteins,and antiviral candidate agents that focus on host receptors.Additionally,this paper provided an overview of the progress in and the mechanisms of various inhibitors in the hope of providing a reference for antiviral drug development and the treatment of dengue fever.
dengue virusdengue feverantiviral drugsvirus protein targethost protein target